The diabetic miniature swine is a widely-recognized translational model for the evaluation of drugs, nutritional therapies, medical devices, and various therapeutic approaches to treatment of diabetes and its metabolic disease complications. Sinclair Research has produced and worked intensively with Type I diabetes mellitus miniature swine since 2001. We are experts in diabetes induction, diabetes maintenance, and conduction of drug or therapeutic pharmacokinetic and pharmacodynamic (PK/PD) studies in the diabetic miniature swine. We offer various types of clamps for your study, including euglycemic, hyperglycemic, hyperinsulinemic, and Bergmann’s.
We currently maintain more than 250 insulin-dependent diabetic miniature swine in-house, enabling us to offer a wide variety of research services using diabetic models; we additionally make the diabetic miniature swine available to industry and academic clients through our sister company, Sinclair Bio Resources.
Why partner with Sinclair Research?
As one of the largest nonclinical CROs in North America, Sinclair Research’s scientific and technical expertise can provide you with the diabetes research services you need, the data you expect, and the customer experience you deserve! Contact our team to discuss your upcoming research and meet with our scientific experts to discuss how to reach your next development milestone.
Miniature Swine Diabetic Model Flexibility
The diabetic miniature swine model is a very versatile model for studies on diabetes management. Sinclair Research has three breeds of miniature swine, Yucatan, Micro-Yucatan, and Sinclair, available for use in a variety studies targeting diabetes-related research areas and therapy types, as listed below.
Our Diabetes Research services include:
Applicable Research Areas
- Type I or Type II diabetes complications
- Insulin resistance
- Wound healing, including delayed healing
- Cataracts and retinopathy
- Dyslipidemia and hypercholesterolemia
- Cardiometabolic syndrome
- Insulin, insulin analogues, insulin sensitizers, β-cell multipliers, cellular therapies
- Small and large molecules, most compounds targeting glucose and lipid activity